Toggle menu

Halt-It Trial

Start date:
August 2014
End date:
November 2016
Co-ordinated by:
London School of Hygiene and Tropical Medicine
Main trial site:
http://haltit.lshtm.ac.uk

HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial

 

Aim

The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.

Trial Design

A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.

Eligibility criteria

Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated

Chief Investigator

Professor Iain Roberts (LSHTM)

Local PI

Dr Matt Reed (RIE)

Research Team

Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Bernadette Gallagher

Senior Research Nurse

More EMERGE Trials

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

Read more

PRECISE-CTCA Trial

To determine the association between high-sensitivity cardiac troponin concentration and obstructive coronary artery disease in patients presenting to the Emergency Department with suspected acute coronary syndrome and cardiac troponin concentration within the normal reference range using CTCA.

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.

Read more

IONA Study

Identification of Novel Psychoactive Substances (IONA)